Last Updated: September 24, 2026

CORDRAN SP Drug Patent Profile

Name: CORDRAN SP Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Cordran Sp patents expire, and when can generic versions of Cordran Sp launch?

Cordran Sp is a drug marketed by Ina Pharms and is included in one NDA.

The generic ingredient in CORDRAN SP is flurandrenolide. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the flurandrenolide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cordran Sp

A generic version of CORDRAN SP was approved as flurandrenolide by PADAGIS ISRAEL on August 30^th, 2016.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CORDRAN SP?
What are the global sales for CORDRAN SP?
What is Average Wholesale Price for CORDRAN SP?

Summary for CORDRAN SP

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	50
Patent Applications:	6,575
DailyMed Link:	CORDRAN SP at DailyMed

Drug patent expirations by year for CORDRAN SP

Pharmacology for CORDRAN SP

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for CORDRAN SP

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ina Pharms	CORDRAN SP	flurandrenolide	CREAM;TOPICAL	012806-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ina Pharms	CORDRAN SP	flurandrenolide	CREAM;TOPICAL	012806-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.